What is claimed is:

1. A hydrophilic hesperitin pro-form of the formula



wherein R is an -H-, and R1 is selected from the group consisting of an organic phosphoric acid salt, an organic sulfuric acid salt, an inorganic phosphoric acid salt and an inorganic sulfuric acid salt, or R1 is an -H- and R is selected from the group consisting of an organic phosphoric acid salt, an organic sulfuric acid salt, an inorganic phosphoric acid salt and an inorganic sulfuric acid salt.

2. A lipophilic hesperitin pro-form of the formula:



wherein R is -H-, and R_1 is selected from the group consisting of a saturated fatty acid moiety, a unsaturated fatty acid moiety, a substituted aliphatic moiety, an aromatic acid moiety, or R_1 is an -H- and R is selected from the group consisting of a saturated fatty acid moiety, a unsaturated fatty acid moiety, a substituted aliphatic moiety, an aromatic acid moiety.

3. The lipophilic hesperitin pro-form of claim 2, wherein said saturated fatty acid moiety, unsaturated fatty acid moiety, substituted aliphatic moiety and aromatic acid moiety comprises from about 1 to about 20 carbons.

4. A pharmaceutical composition suitable for topical or oral administration in an individual, said composition comprising a hydrophilic hesperetin pro-form and a pharmaceutically acceptable carrier, wherein said hesperitin pro-form has the formula:



wherein R is an -H-, and R1 is selected from the group consisting of an organic phosphoric acid salt, an organic sulfuric acid salt, an inorganic phosphoric acid salt and an inorganic sulfuric acid salt, or R1 is an -H- and R is selected from the group consisting of an organic phosphoric acid salt, an organic sulfuric acid salt, an inorganic phosphoric acid salt and an inorganic sulfuric acid salt.

5. A pharmaceutical composition suitable for topical or oral administration in an individual, said composition comprising a lipophilic hesperetin pro-form and a pharmaceutically acceptable carrier, wherein said hesperitin pro-form has the formula:



wherein R is -H-, and R1 is selected from the group consisting of a saturated fatty acid moiety, a unsaturated fatty acid moiety, a substituted aliphatic moiety, an aromatic acid moiety, or R1 is an -H- and R is selected from the group consisting of a saturated fatty acid moiety, a unsaturated fatty acid moiety, a substituted aliphatic moiety, an aromatic acid moiety.

6. A method of treating a subject having or at risk of having a cell proliferative disorder, comprising administering to the subject a therapeutically effective amount of a hesperetin pro-form.

7. The method of claim 6, wherein said hesperetin proform is a hydrophilic hesperitin pro-form.

8. The method of claim 7, wherein said hesperetin has the formula



wherein R is an -H-, and R1 is selected from the group consisting of an organic phosphoric acid salt, an organic sulfuric acid salt, an inorganic phosphoric acid salt and an inorganic sulfuric acid salt, or R1 is an -H- and R is selected from the group consisting of an organic phosphoric acid salt, an organic sulfuric acid salt, an inorganic phosphoric acid salt and an inorganic sulfuric acid salt.

9. The method of claim 6, wherein said hesperetin proform is a lipophilic hesperitin pro-form.

10. The method of claim 9, wherein said hesperetin has the formula:



wherein R is -H-, and R1 is selected from the group consisting of a saturated fatty acid moiety, a unsaturated fatty acid moiety, a substituted aliphatic moiety, an aromatic acid moiety, or R1 is an -H- and R is selected from the group consisting of a saturated fatty acid moiety, a unsaturated fatty acid moiety, a substituted aliphatic moiety, an aromatic acid moiety.

11. The method of claim 6, wherein said cell proliferative disorder is selected from the group consisting of breast cancer, skin cancer, uterine cancer, testicular cancer, lung cancer, prostate cancer, liver cancer, and uterine cancer.

12. The method of claim 6, wherein said subject is a human.

13. A method of decreasing oxidative stress in a subject having a disorder associated with oxidative stress, comprising administering to the subject a therapeutically effective amount of a hesperitin pro-form.

14. The method of claim 13, wherein said disorder is selected from the group consisting of diabetes, cerebral anemia, and pelioma.

15. A method of treating a subject having or at risk of having a disorder associated with sebacous gland activity, comprising administering to the subject a therapeutically effective amount of a hesperetin pro-form.

16. The method of claim 14, wherein said disorder associated with sebaceous gland activity is selected from the group consisting of increased sebum production, acne of the skin and acne of the scalp.

17. A method of treating a subject having or at risk of having a cardiovascular disorder, comprising administering to the subject a therapeutically effective amount of a hesperetin pro-form.

18. The method of claim 17, wherein said cardiovascular disorder is selected from the group consisting of atherosclerosis and hypercholesteremia.